Home Cart Sign in  
Chemical Structure| 518-34-3 Chemical Structure| 518-34-3

Structure of Tetrandrine
CAS No.: 518-34-3

Chemical Structure| 518-34-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tetrandrine, a bis-benzylisoquinoline alkaloid derived from Stephania tetrandra, is a calcium channel blocker that inhibits voltage-gated Ca2+ current (ICa) and Ca2+-activated K+ current.

Synonyms: NSC-77037; d-Tetrandrine; TTD.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tetrandrine

CAS No. :518-34-3
Formula : C38H42N2O6
M.W : 622.75
SMILES Code : CN1CCC2=CC(OC)=C(O3)C=C2[C@]1([H])CC4=CC=C(OC5=C(OC)C=CC(C[C@@]6([H])C7=C3C(OC)=C(OC)C=C7CCN6C)=C5)C=C4
Synonyms :
NSC-77037; d-Tetrandrine; TTD.
MDL No. :MFCD08689909
InChI Key :WVTKBKWTSCPRNU-KYJUHHDHSA-N
Pubchem ID :73078

Safety of Tetrandrine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Calcium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 2 μg/mL 12 hours To detect TET-CTM/L induced apoptosis in HepG2 cells, results showed that TET-CTM/L significantly induced apoptosis. PMC10822770
Huh7 cells 0, 0.5, 1, 2 or 4 μM 24 hours Tetrandrine significantly inhibited the migration and invasion of Huh7 cells PMC5769468
HCCLM9 cells 0, 0.5, 1, 2 or 4 μM 24 hours Tetrandrine significantly inhibited the migration and invasion of HCCLM9 cells PMC5769468
Hep3B cells 0, 0.5, 1, 2 or 4 μM 24 hours Tetrandrine significantly inhibited the migration and invasion of Hep3B cells PMC5769468
HepG2 cells 0.675~20 μg/mL 24 hours To evaluate the cytotoxicity of TET-CTM/L against HepG2 cells, results showed that TET-CTM/L has significant anti-tumor efficacy. PMC10822770
Murine peritoneal macrophages 100 μM 3 hours Tetrandrine inhibited NLRP3 inflammasome activation and reduced the release of IL-1β and IL-18. PMC9061833
Cardiac myocytes 10 µM 30 minutes Tetrandrine significantly inhibited Ang II-induced ROS generation PMC2829222
K562 2 μM 48 hours Tetrandrine inhibited the proliferation of K562 cells and induced cell cycle arrest at the G0/G1 phase. PMC5920096
THP-1 2 μM 48 hours Tetrandrine inhibited the proliferation of THP-1 cells and induced cell cycle arrest at the G0/G1 phase. PMC5920096
HL60 2 μM 48 hours Tetrandrine inhibited the proliferation of HL60 cells and induced cell cycle arrest at the G0/G1 phase. PMC5920096
U937 2 μM 48 hours Tetrandrine inhibited the proliferation of U937 cells and induced cell cycle arrest at the G0/G1 phase. PMC5920096
K562 cells 2 μM 48 hours Tetrandrine induced cell cycle arrest and megakaryocyte differentiation in K562 cells via activation of autophagy. PMC5715583
6133 cells 2 μM 48 hours Tetrandrine induced cell cycle arrest and megakaryocyte differentiation in 6133 cells via activation of autophagy. PMC5715583
CMK cells 2 μM 48 hours Tetrandrine induced cell cycle arrest and megakaryocyte differentiation in CMK cells via activation of autophagy. PMC5715583
HEL cells 2 μM 48 hours Tetrandrine induced cell cycle arrest and megakaryocyte differentiation in HEL cells via activation of autophagy. PMC5715583
RAW264.7 cells 0.3 μM 6 hours Tetrandrine significantly inhibited RANKL-induced osteoclastogenesis and enhanced the ubiquitination and degradation of Syk through the AhR/c-src/c-Cbl signaling pathway. PMC6427010
BMMs 0.3 μM 6 hours Tetrandrine significantly inhibited RANKL-induced osteoclastogenesis and enhanced the ubiquitination and degradation of Syk through the AhR/c-src/c-Cbl signaling pathway. PMC6427010
Human breast cancer cells (MDA-MB-231, MDA-MB-468, MCF-7) 0-5 μM 72 hours Tetrandrine alone or in combination with H89 exhibited antitumor effects on various cancer cells, and the combination showed synergistic effects. PMC5987653
Human hepatoma cells (Hep3B, Huh7) 0-5 μM 72 hours Tetrandrine alone or in combination with H89 exhibited antitumor effects on various cancer cells, and the combination showed synergistic effects. PMC5987653
Human renal carcinoma cells (769-P, ACHN, 786-O) 0-5 μM 72 hours Tetrandrine alone or in combination with H89 exhibited antitumor effects on various cancer cells, and the combination showed synergistic effects. PMC5987653
Human colon cancer cells (LOVO, HCT116) 0-5 μM 72 hours Tetrandrine alone or in combination with H89 exhibited antitumor effects on various cancer cells, and the combination showed synergistic effects. PMC5987653

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HCCLM9 subcutaneous tumor xenograft model Oral 30 mg/kg every other day for 37 days Tetrandrine significantly inhibited lung metastasis of HCCLM9 cells in vivo PMC5769468
Mice Thy1-hTau.P301S transgenic mice Intraperitoneal injection 2.5 mg/kg, 5 mg/kg, 10 mg/kg Every two days for two months To study the effect of Tetrandrine on tau aggregation and cognitive dysfunction, results showed that Tetrandrine reduced tau aggregation in a dose-dependent manner and improved memory function in mice. PMC9587578
C57BL/6J mice Silicosis model Gavage 50 mg/kg or 100 mg/kg Once daily for 4 weeks Tetrandrine alleviated pulmonary inflammation and fibrosis, and improved lung function in silicosis mice. PMC9061833
Nude mice (BALB/c) MDA-MB-231 xenograft model Oral and intraperitoneal injection 25 mg/kg Every other day for 28 days The combination of Tetrandrine and H89 significantly inhibited tumor growth in vivo, showing synergistic effects. PMC5987653
C57/B6 mice Aortic banding (AB) model Oral gavage 50 mg/kg/day Three times a day for one week Tetrandrine significantly attenuated AB-induced cardiac hypertrophy, reduced heart weight/body weight and lung weight/body weight ratios, and inhibited fibrosis and inflammatory response PMC2829222
Nude mice Subcutaneous tumor xenograft model Oral 25 mg/kg or 50 mg/kg Once daily for 13 days Tetrandrine significantly inhibited tumor growth and promoted tumor cell differentiation. PMC5920096
Nude mice HepG2 xenograft tumor model Intraperitoneal injection 1.5 mg/kg Once every two days for 24 days To evaluate the in vivo anti-tumor efficacy of TET-CTM/L, results showed that TET-CTM/L significantly inhibited tumor growth. PMC10822770
Nude mice K562 tumor xenograft model Oral 50 mg/kg Once daily for 23 days Tetrandrine significantly inhibited the growth of K562 tumors, reducing tumor volume and weight. PMC5715583

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04308317 Corona Virus Disease 2019,COVI... More >>D-19 Less << PHASE4 UNKNOWN 2021-05-01 Tetrandrine Tablets, Jinhua, Z... More >>hejiang, 321000, China Less <<
NCT05697029 COVID-19 PHASE4 WITHDRAWN 2025-12-12 Peking University Third Hospit... More >>al, Beijing, Beijing, 100191, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.61mL

0.32mL

0.16mL

8.03mL

1.61mL

0.80mL

16.06mL

3.21mL

1.61mL

References

 

Historical Records

Categories